Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis

NCT00151892 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00151892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00151892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
April 8, 2005
Completion date
September 7, 2009
Enrollment
829 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis